Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

BLA 125197 Provenge - Provenge, March 7, 2010

From:             Greeley, George
Sent:                Sunday, March 07, 2010 1:45 PM
To:                    Tull, Lori
Cc:                    Stowe, Ginneh D.
Subject:           BLA 125197 Provenge
Importance:    High

Hi Lori,

The Provenge (sipuleucel-T) full waiver was reviewed by the PeRC PREA Subcommittee on January 27, 2010. 

The Division recommended a full waiver because disease/condition does not exist in children.   

The PeRC agreed with the Division to grant a full waiver for this product.

Thank you.

George Greeley
Regulatory Health Project Manager
Pediatric and Maternal Health Staff
10903 New Hampshire Avenue
Bldg. 22, Room 6467
Silver Spring, MD 20993-0002
Phone: 301.796.4025
Please consider the environment before printing this e-mail.

Page Last Updated: 03/24/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English